Cubist Systematic Strategies’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $17.7K | Buy |
+10,789
| New | +$12K | ﹤0.01% | 2903 |
|
|
2024
Q2 | – | Sell |
-80,063
| Closed | -$191K | – | 3112 |
|
|
2024
Q1 | $191K | Sell |
80,063
-307,177
| -79% | -$756K | ﹤0.01% | 3093 |
|
|
2023
Q4 | $1.29M | Sell |
387,240
-193,732
| -33% | -$519K | 0.01% | 1847 |
|
|
2023
Q3 | $2.17M | Buy |
580,972
+560,998
| +2,809% | +$2.59M | 0.02% | 1316 |
|
|
2023
Q2 | $85.3K | Sell |
19,974
-139,440
| -87% | -$823K | ﹤0.01% | 3021 |
|
|
2023
Q1 | $1.09M | Sell |
159,414
-43,488
| -21% | -$338K | 0.01% | 2116 |
|
|
2022
Q4 | $1.61M | Sell |
202,902
-21,404
| -10% | -$165K | 0.01% | 2046 |
|
|
2022
Q3 | $2.16M | Buy |
224,306
+196,496
| +707% | +$1.99M | 0.01% | 1935 |
|
|
2022
Q2 | $201K | Buy |
27,810
+9,036
| +48% | +$78.6K | ﹤0.01% | 3695 |
|
|
2022
Q1 | $242K | Sell |
18,774
-119,358
| -86% | -$1.52M | ﹤0.01% | 2957 |
|
|
2021
Q4 | $2.21M | Buy |
138,132
+118,416
| +601% | +$2.07M | 0.02% | 1278 |
|
|
2021
Q3 | $317K | Sell |
19,716
-21,184
| -52% | -$311K | ﹤0.01% | 2325 |
|
|
2021
Q2 | $566K | Sell |
40,900
-30,466
| -43% | -$431K | 0.01% | 1925 |
|
|
2021
Q1 | $1.04M | Buy |
71,366
+60,466
| +555% | +$1.03M | 0.01% | 1511 |
|
|
2020
Q4 | $189K | Sell |
10,900
-2,118
| -16% | -$37.7K | ﹤0.01% | 2259 |
|
|
2020
Q3 | $239K | Buy |
+13,018
| New | +$242K | ﹤0.01% | 2063 |
|
|
2020
Q2 | – | Sell |
-112,634
| Closed | -$1.83M | – | 2400 |
|
|
2020
Q1 | $1.83M | Buy |
112,634
+67,193
| +148% | +$1.24M | 0.05% | 508 |
|
|
2019
Q4 | $818K | Buy |
45,441
+17,603
| +63% | +$325K | 0.02% | 1287 |
|
|
2019
Q3 | $564K | Buy |
27,838
+24
| +0.1% | +$480 | 0.01% | 1238 |
|
|
2019
Q2 | $615K | Buy |
27,814
+12,671
| +84% | +$220K | 0.01% | 1347 |
|
|
2019
Q1 | $207K | Sell |
15,143
-446
| -3% | -$5.95K | 0.01% | 1755 |
|
|
2018
Q4 | $141K | Sell |
15,589
-17,289
| -53% | -$200K | 0.01% | 1664 |
|
|
2018
Q3 | $542K | Buy |
32,878
+9,235
| +39% | +$164K | 0.03% | 776 |
|
|
2018
Q2 | $331K | Buy |
+23,643
| New | +$338K | 0.02% | 1023 |
|
|
2018
Q1 | – | Sell |
-11,033
| Closed | -$97K | – | 1858 |
|
|
2017
Q4 | $97K | Buy |
+11,033
| New | +$118K | 0.01% | 1686 |
|
|
2017
Q3 | – | Sell |
-12,900
| Closed | -$185K | – | 1858 |
|
|
2017
Q2 | $185K | Buy |
+12,900
| New | +$248K | 0.01% | 1317 |
|
|
2016
Q4 | – | Sell |
-5,623
| Closed | -$151K | – | 1731 |
|
|
2016
Q3 | $151K | Buy |
+5,623
| New | +$153K | 0.01% | 1365 |
|
|
2015
Q1 | – | Sell |
-14,414
| Closed | -$235K | – | 1907 |
|
|
2014
Q4 | $235K | Buy |
+14,414
| New | +$203K | 0.01% | 1394 |
|
Other funds holding CHRS
TCM
KKRC
CM
CWG
PAM
Cubist Systematic Strategies's CHRS Position: Q3 2025 in Review
Cubist Systematic Strategies opened a new position in Coherus Oncology (CHRS) in Q3 2025: 10,789 shares worth $17.7K. The stake represents ﹤0.01% of the portfolio and ranks #2903 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in CHRS as recently as Q1 2024.
Cubist Systematic Strategies first reported a position in CHRS in Q4 2014 and has held it in 28 quarters since. The position peaked at $2.21M in Q4 2021. 114 funds tracked by Wall St. Rank hold CHRS as of Q3 2025.
- Cubist Systematic Strategies held 10,789 shares of Coherus Oncology worth $17.7K as of Q3 2025.
- Coherus Oncology was a new Cubist Systematic Strategies position in Q3 2025.
- Coherus Oncology made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2903 holding.
- Cubist Systematic Strategies first reported a position in Coherus Oncology in Q4 2014 and has held it in 28 quarters since.
- Cubist Systematic Strategies's Coherus Oncology position peaked at $2.21M in Q4 2021.
- 114 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2025.
Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.